文献速递瓣膜外科

老年患者从微创二尖瓣手术中获益:围手术期风险管理至关重要

Elderly patients benefit from minimally invasive mitral valve surgery: perioperative risk management matters.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2024-01-01

该单中心回顾性分析纳入131例≥75岁经右胸小切口行内镜微创二尖瓣手术的连续老年患者,分为修复组(85例)与置换组(46例),中位随访3.8年。置换组体外循环时间(128.7分钟 vs 155.9分钟,P=0.012)和主动脉阻断时间(84.9分钟 vs 124.1分钟,P=0.005)显著更长,再干预出血更多(10.9% vs 0%,P=0.005),但两组术后病程无其他显著差异,1年和5年生存率分别为97.6%和88.6%,组间无显著差异。作者认为微创二尖瓣手术是脆弱老年患者的优良治疗选择,其经验提示置换在死亡率和主要不良心脑血管事件方面与修复等效,经验和标准化术前筛查是获得最佳结果的必要条件。

要点

  • ≥75岁患者行内镜微创二尖瓣手术,1年生存率97.6%、5年生存率88.6%。
  • 置换组体外循环和主动脉阻断时间显著长于修复组,出血再干预率更高。
  • 作者经验提示置换与修复在死亡率和主要不良心脑血管事件方面等效。

核心结论

  • 微创二尖瓣手术是脆弱老年患者的优良治疗选择,短期和长期结果均优良。
  • 作者经验提示置换在死亡率和主要不良心脑血管事件方面与修复等效。
  • 经验和标准化术前筛查是获得最佳结果的必要条件。

研究设计与样本

  • 单中心回顾性分析,纳入131例≥75岁经右胸小切口行内镜微创二尖瓣手术的连续老年患者。
  • 所有拟行微创瓣膜手术的患者均接受标准化术前筛查。
  • 分为修复组(85例)和置换组(46例),评估生存率和术后病程。

主要发现

  • 平均年龄79±2.9岁,中位随访时间3.8年。
  • 置换组体外循环时间128.7分钟 vs 修复组155.9分钟,P=0.012,置换组显著更长。
  • 置换组主动脉阻断时间84.9分钟 vs 修复组124.1分钟,P=0.005,置换组显著更长。
  • 置换组因出血再干预10.9% vs 修复组0%,P=0.005,置换组更多。
  • 两组术后病程无其他显著差异;1年和5年生存率分别为97.6%和88.6%,两组间无显著差异,4个月与12个月随访间亦无差异。

临床怎么用

  • 作者认为微创二尖瓣手术是脆弱老年患者的优良治疗选择。
  • 作者经验提示置换在死亡率和主要不良心脑血管事件方面与修复等效。
  • 作者认为经验和标准化术前筛查是获得最佳结果的必要条件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The goal was to assess the single-centre results of minimally invasive mitral valve surgery (MIMVS) in the elderly population. METHODS: All patients referred for minimally invasive valve surgery underwent a standardized preoperative screening. We performed a retrospective analysis of 131 consecutive elderly patients (≥75 years) who underwent endoscopic MIMVS through a right mini-thoracotomy. Survival and postoperative course were assessed in 2 groups: a repair group and a replacement group. RESULTS: Eighty-five patients underwent mitral valve repair, and 46 had mitral valve replacement. The mean age was 79 ± 2.9 years, and the median follow-up duration was 3.8 years. The cardiopulmonary bypass time (128.7 min vs 155.9 min, P = 0.012) and the cross-clamp time (84.9 min vs 124.1 min, P = 0.005) were significantly longer in the replacement group. Except for more reinterventions for bleeding in the replacement group (10.9% vs 0%, P = 0.005), there were no significant differences in the postoperative course between the 2 groups. Low mortality rates at the midterm follow-up were observed in both groups, and no differences were observed between the 4-and the 12-month follow-up. Survival rates after 1 year and 5 years were 97.6% and 88.6%, respectively, with no significant differences between the 2 groups. CONCLUSIONS: MIMVS is an excellent treatment option in vulnerable elderly patients with excellent short- and long-term results. Although other studies suggest that repair could be superior to replacement even in older patients, our experience suggests that replacement is equivalent to repair in terms of mortality and major adverse cardiac and cerebrovascular events. Experience and standardized preoperative screening are mandatory to achieve optimal results.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Cocchieri R, Mousavi I, Verbeek EC, et al. Elderly patients benefit from minimally invasive mitral valve surgery: perioperative risk management matters. Interdiscip Cardiovasc Thorac Surg. 2024. PMID: 38191999. doi:10.1093/icvts/ivad211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。